A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)

Inclusion Criteria: Only participants who meet all the inclusion criteria will be enrolled into the trial: * Group 1: Healthy adult aged 18-35 years at the time of first study vaccination * Group 2-6: Healthy child aged 5-17 months at the time of first study vaccination * Group 1: Female participants must be non-pregnant (as demonstrated by a negative urine pregnancy . test), and practice continuous effective contraception until three months after the final study vaccination * Participant or parent/guardian provides signed/thumb-printed informed consent * Participant (and parent/guardian for child participants) resident in the study area villages, and anticipated to be available for vaccination and the duration of follow-up - Exclusion Criteria: * The participant may not enter the trial if ANY of the following apply: * Clinically significant congenital abnormalities as judged by the PI or other delegated individual. * Clinically significant skin disorder (psoriasis, contact dermatitis, etc.), cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurological illness as judged by the PI or other delegated individual. * History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ). * Children with weight-for-age Z score of less than -3 or other clinical signs of malnutrition. * History of allergic reaction, significant IgE-mediated event, or anaphylaxis to immunisati…